QPPV.COM KNOWLEDGE ASSESSMENT

Acalabrutinib: Discovery, Development, Safety and Pharmacovigilance — Knowledge Assessment

Test your understanding of the concepts covered by Acalabrutinib: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient on acalabrutinib reports palpitations and near-syncope. Which response is most appropriate?
Question 2 of 10 How should the 2015–2016 Acerta transaction figures be interpreted in an account of acalabrutinib's development?
Question 3 of 10 What conclusion should be avoided when interpreting ELEVATE-TN?
Question 4 of 10 The US tablet label reports serious or Grade 3 or higher infections in 29% of a pooled 2,055-patient exposure population. How should this figure be used?
Question 5 of 10 A patient develops febrile neutropenia after a cycle of acalabrutinib–bendamustine–rituximab. Which case-assessment principle is most appropriate?
Question 6 of 10 A patient reports taking the same Calquence brand name before and after a transfer between markets. Disease control changes after the transfer. Which additional information is particularly important to investigate?
Question 7 of 10 The assessed US label explicitly names drug-induced liver injury, while the assessed EU SmPC section 4.8 does not contain an identically named entry. What conclusion is justified?
Question 8 of 10 When assessing whether a reported reaction is listed in product information, which approach is most defensible?
Question 9 of 10 A spontaneous report describes 'Calquence-associated bleeding' in a patient who may also have received venetoclax and an antithrombotic. What exposure information is most useful to establish?
Question 10 of 10 Why can spontaneous-report counts alone not establish the incidence of an acalabrutinib adverse reaction?

Select an answer to continue.

QPPV.com